Astrocytomas represent the most prevalent primary parenchymal neoplasms of the human central nervous system, arising from or phenotypically resembling non-neuronal supportive macroglia known as astrocytes. These neoplasms exhibit an extraordinary spectrum of biological behavior, ranging from indolent, surgically curable circumscribed lesions in pediatric cohorts to relentlessly invasive, treatment-refractory diffuse malignancies in adults. Navigating the diagnostic and therapeutic landscape of astrocytoma requires a sophisticated synthesis of clinical neurology, neurosurgical oncology, neuropathology, and modern molecular genetics.
Astrocytoma
1. Concise Definition
An astrocytoma is a primary central nervous system neoplasm composed of neoplastic cells demonstrating phenotypic, ultrastructural, and immunophenotypic features of astrocytes. Biologically, astrocytic tumors are characterized by their cellular origin within the neuroepithelial lineage and their propensity either to form well-demarcated nodular masses or to diffusely infiltrate pre-existing white and gray matter tracts throughout the brain and spinal cord.
In modern contemporary neuropathology, astrocytomas are categorized into distinct biological entities governed by integrated histopathological criteria and defining genomic alterations. Whereas circumscribed astrocytic tumors, such as pilocytic astrocytoma, generally maintain non-diffuse borders and follow an indolent clinical course, diffuse astrocytic tumors display an inherent biological drive toward extensive microvascular proliferation, invasion of normal parenchyma, evasion of apoptotic pathways, and progressive evolutionary transformation toward higher malignancy grades.
2. Etymology & Linguistic Origin
The term astrocytoma derives linguistically from classical Greek and modern pathological nomenclature. The primary root stems from the ancient Greek ἄστρον (astron, meaning “star”), combined with the Greek biological root κύτος (kytos, denoting a “hollow vessel,” which later evolved in modern histology to mean “cell”). This morphological descriptor reflects the multi-radiating, star-shaped cytoplasmic processes characteristic of quiescent protoplasmic and fibrous astrocytes observed under early light microscopy.
The suffix -oma originates from the Greek suffix -ωμα (-ōma), employed systematically in medical nosology to designate a morbid growth, tumefaction, or true biological neoplasm. The term entered formal neuropathological discourse in the early twentieth century through the pioneering taxonomic works of neurosurgeon Harvey Cushing and neuropathologist Percival Bailey, who sought to categorize intracranial neoplasms based upon embryological and cytological histogenesis.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed in the International Phonetic Alphabet (IPA) as /ˌæs.troʊ.saɪˈtoʊ.mə/ (American English) or /ˌæs.trə.saɪˈtəʊ.mə/ (British English). Syllabic stress falls predominantly on the penultimate syllable (-to-), with secondary stress allocated to the initial syllable (as-).
Grammatical Form: Count noun, singular. Pluralization is standardly rendered as astrocytomas, or occasionally in classical pathological texts as astrocytomata (employing the Greek plural inflection). The adjectival derivative is astrocytic (/ˌæs.trəˈsɪt.ɪk/), frequently applied to describe architectural patterns, cellular morphology, or associated reactive gliosis (e.g., “diffuse astrocytic proliferation”).
4. Detailed Conceptual Explanation
Astrocytes constitute the most abundant glial population in the central nervous system, performing indispensable physiological tasks that include maintaining the blood-brain barrier via perivascular end-feet, regulating neurotransmitter reuptake (notably glutamate), modulating local microvascular blood flow, and providing structural and metabolic support to adjacent neuronal circuits. Neoplastic transformation of this lineage yields an astrocytoma, which deregulates these fundamental supportive functions and substitutes homeostatic equilibrium with unchecked cell proliferation, tissue destruction, and profound disruption of the surrounding neurovascular unit.
The pathophysiological hallmark of diffuse astrocytomas is their insidious capacity for single-cell parenchymal infiltration. Neoplastic astrocytes dissociate from the primary tumor nidus, navigating along preferential anatomical pathways termed the secondary structures of Scherer. These routes include subpial surfaces, perivascular Virchow-Robin spaces, and longitudinally organized myelinated axon bundles such as the corpus callosum and internal capsule. Because individual malignant cells routinely migrate centimeters away from the radiographically visible core lesion, diffuse astrocytomas are intrinsically non-resectable in the strictly curative surgical sense, guaranteeing local or distant microscopic recurrence even after gross total radiological excision.
The conceptual framework governing astrocytoma diagnosis underwent a profound paradigm shift with the release of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System (fifth edition, 2021). Historically classified solely on histological features such as cellular atypia, mitotic activity, microvascular proliferation, and necrosis, astrocytomas are now fundamentally defined by their molecular and cytogenetic landscape. For example, the presence or absence of mutations in the metabolic enzyme genes IDH1 or IDH2 (isocitrate dehydrogenase) bifurcates adult diffuse astrocytomas into biologically distinct diseases. An IDH-mutant astrocytoma represents an epigenetically, biologically, and clinically unique disease entity with a markedly superior prognosis compared to morphologically identical IDH-wildtype neoplasms, which are now recognized as molecular glioblastomas regardless of histological low-grade appearance.
At the physiological and metabolic level, astrocytic neoplasms commandeer the surrounding microenvironment. Tumors remodel extracellular matrix architecture via the hypersecretion of matrix metalloproteinases, induce profound immunosuppression through the recruitment of tumor-associated macrophages and myeloid-derived suppressor cells, and trigger reactive cerebral edema. This edema results from hyperpermeable, dysplastic neo-vessels driven by vascular endothelial growth factor (VEGF) hypersecretion, resulting in localized tissue distortion, elevated intracranial pressure, and severe progressive focal neurological deficits.
5. Historical Development
The systematic study of astrocytomas parallels the broader evolution of cellular pathology and clinical neurosurgery. Prior to the mid-nineteenth century, intracranial growths were indiscriminately labeled as “fungus cerebri” or soft brain cancers without regard to cellular lineage. In 1863, German pathologist Rudolf Virchow introduced the concept of neuroglia as an interstitial connective matrix supporting brain parenchyma, postulating that certain brain tumors arose directly from this cellular glue, which he designated as “gliomas.”
The definitive taxonomic architecture of astrocytomas was established in 1926 by Percival Bailey and Harvey Cushing in their landmark monograph A Classification of the Tumors of the Glioma Group on a Histogenetic Basis. Bailey and Cushing correlated histopathological morphologies with embryological precursor cells, identifying astrocytomas as distinct from medulloblastomas, ependymomas, and oligodendrogliomas. They further recognized the profound clinical heterogeneity between slowly progressive fibrillary astrocytomas and the aggressively lethal variant they designated “glioblastoma multiforme.”
Throughout the mid-to-late twentieth century, grading systems were refined to provide therapeutic and prognostic utility. James W. Kernohan proposed a four-tiered numerical classification in 1949, which was subsequently modified into the three-tiered St. Anne-Mayo grading system by Daumas-Duport and colleagues in 1988. The St. Anne-Mayo system utilized four objective histological criteria: nuclear atypia, mitoses, endothelial proliferation, and necrosis. The World Health Organization subsequently synthesized these systems, establishing standard histological criteria in editions published in 1979, 1993, 2000, and 2007.
The modern era commenced in 2008 with the genomic sequencing of glioblastoma by The Cancer Genome Atlas (TCGA) and the discovery by Parsons and colleagues of recurrent somatic mutations in IDH1 and IDH2 in secondary and lower-grade diffuse astrocytomas. These genomic insights culminated in the 2016 and 2021 WHO Classifications, which permanently dismantled the purely microscopic taxonomy in favor of integrated, layered histomolecular diagnoses, establishing a new global standard for neuro-oncological medicine.
6. Theoretical Foundations
Contemporary understanding of astrocytoma pathogenesis rests upon three interconnected theoretical models: the neural stem cell origin hypothesis, the multistep genetic progression paradigm, and the epigenetic oncometabolite theory.
The neural stem cell hypothesis posits that astrocytomas originate not from mature, terminally differentiated astrocytes, but rather from multipotent neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) residing within specialized neurogenic niches, most notably the subventricular zone (SVZ) lining the lateral ventricles. Somatic driver mutations accumulating in these self-renewing, highly plastic progenitor pools allow the cells to escape physiological contact inhibition, migrate outward into the cerebral cortex or subcortical white matter, and commit aberrantly toward an astrocytic lineage.
The multistep genetic progression paradigm explains how low-grade diffuse astrocytomas evolve into high-grade, lethal lesions over time. In IDH-mutant astrocytic lineages, the early initiating events almost invariably comprise heterozygous missense mutations in IDH1 (predominantly codon R132H) or IDH2 (codon R172), coupled with inactivating mutations in TP53 and transcriptional repressor ATRX (alpha-thalassemia/mental retardation syndrome X-linked). Over variable intervals of months to years, genomic instability drives secondary alterations, including homozygous deletion of CDKN2A/B, PI3K/AKT pathway alterations, and chromosomal aneuploidies, culminating in high-grade transformation characterized by uncontrolled cellular kinetics and metabolic exhaustion.
The epigenetic oncometabolite theory provides the mechanistic link between metabolic alteration and malignant transformation. Neoplastic IDH1/2 mutations confer a neomorphic enzymatic function: instead of converting isocitrate to alpha-ketoglutarate (α-KG), the mutant enzyme reduces α-KG into the aberrant oncometabolite D-2-hydroxyglutarate (D-2-HG). Pathological accumulation of D-2-HG competitively inhibits α-KG-dependent dioxygenases, including histone demethylases and the ten-eleven translocation (TET) family of DNA methyltransferases. This enzyme blockade induces extensive genome-wide DNA hypermethylation—the glioma CpG island methylator phenotype (G-CIMP)—locking neural progenitor cells in an undifferentiated, highly proliferative, transformable state.
7. Key Components, Types & Dimensions
Astrocytic neoplasms are structurally, clinically, and genetically heterogeneous. Under the current neuro-oncological taxonomy, they are stratified into circumscribed tumors, adult-type diffuse astrocytomas, and pediatric-type gliomas:
- Pilocytic Astrocytoma (CNS WHO Grade 1): A predominantly pediatric, circumscribed, slow-growing neoplasm frequently localized to the cerebellum, optic pathway, or brainstem. Histologically characterized by biphasic architecture with compact bipolar piloid cells, microcysts, Rosenthal fibers, and eosinophilic granular bodies. Driven by MAPK pathway alterations, most commonly the KIAA1549-BRAF gene fusion, and typically curable via complete surgical resection.
- Pleomorphic Xanthoastrocytoma (CNS WHO Grades 2 and 3): A circumscribed supratentorial astrocytic tumor typically manifesting in children and young adults with chronic intractable epilepsy. Exhibits marked cytological pleomorphism, lipid-laden xanthomatous astrocytes, eosinophilic granular bodies, and a rich reticulin network, often harboring the activating BRAF V600E point mutation.
- Subependymal Giant Cell Astrocytoma (CNS WHO Grade 1): A benign, periventricular astrocytic neoplasm arising almost exclusively in patients with the genetic syndrome tuberous sclerosis complex (TSC1/TSC2 mutation), displaying large ganglioid, gemistocytic-like cells and requiring surveillance for acute hydrocephalus.
- Astrocytoma, IDH-Mutant (CNS WHO Grades 2, 3, and 4): An adult-type diffuse glioma defined by co-occurring IDH1/2 mutation, TP53 mutation, and loss of nuclear ATRX expression, with intact 1p/19q chromosomal arms. Graded across an intra-entity continuum:
- Grade 2: Mild atypia, low proliferative index, absence of mitoses, and favorable relative survival.
- Grade 3: Brisk mitotic activity, significant nuclear atypia, and heightened cellularity.
- Grade 4: Microvascular proliferation, pseudopalisading necrosis, or molecular high-grade features defined specifically by homozygous deletion of the CDKN2A/B locus on chromosome 9p21.
- Pediatric-Type Diffuse Astrocytomas: Distinct molecular classes including diffuse astrocytoma with MYB or MYBL1 alteration (low-grade), and diffuse midline glioma harboring H3 K27M alterations (high-grade, universally aggressive brainstem/thalamic tumors).
8. Examples & Illustrative Cases
Case 1: Young Adult with Low-Grade Diffuse Astrocytoma. A 28-year-old software architect experiences a first-time generalized tonic-clonic seizure preceded by an olfactory aura. Neurological examination is completely unremarkable. Contrast-enhanced magnetic resonance imaging (MRI) reveals a non-enhancing, T2/FLAIR-hyperintense, well-demarcated infiltrative lesion centered within the left frontal lobe cortex and underlying subcortical white matter. The patient undergoes awake craniotomy with intraoperative cortical and subcortical functional speech mapping, achieving a near-total resection. Neuropathology demonstrates a moderately cellular fibrillary astrocytic neoplasm lacking mitoses, necrosis, or microvascular proliferation. Molecular diagnostic testing reveals an IDH1 R132H mutation, loss of nuclear ATRX via immunohistochemistry, strong p53 immunoreactivity, absence of 1p/19q co-deletion, and intact CDKN2A/B alleles. The definitive diagnosis is Astrocytoma, IDH-mutant, CNS WHO Grade 2. The patient enters post-surgical surveillance with serial neuroimaging and anticonvulsant management.
Case 2: Middle-Aged Individual with High-Grade Progression. A 46-year-old woman presents to the emergency department following three weeks of worsening morning headaches, progressive right-sided hemiparesis, and subtle expressive aphasia. She has a documented clinical history of a Grade 2 astrocytoma resected seven years prior, treated at that time with observation alone. Neuroimaging demonstrates a large, heterogeneous mass within the previous resection margin, displaying peripheral ring enhancement, a central non-enhancing core of necrosis, extensive perilesional vasogenic edema, and local mass effect. Stereotactic craniotomy and repeat debulking are performed. Histological assessment confirms brisk mitotic figures, dense cellularity, pseudopalisading necrosis, and prominent microvascular glomeruloid proliferations. Molecular sequencing preserves the initial IDH1 mutation and ATRX loss, while fluorescence in situ hybridization (FISH) demonstrates newly acquired homozygous deletion of CDKN2A/B. The integrated diagnosis is Astrocytoma, IDH-mutant, CNS WHO Grade 4, prompting immediate adjuvant chemoradiotherapy.
9. Measurement & Assessment
The diagnostic verification and clinical monitoring of astrocytomas demand an integrated workflow combining advanced neuroimaging, intraoperative tissue acquisition, histopathological inspection, and high-throughput molecular pathology:
- Magnetic Resonance Imaging (MRI): Standard multi-parametric protocols represent the clinical diagnostic foundation. T1-weighted sequences delineate gross anatomical borders; T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) sequences define the full extent of non-enhancing infiltrative disease and surrounding edema (FLAIR/T2 mismatch sign is highly specific for IDH-mutant, non-co-deleted astrocytomas). T1-weighted sequences following intravenous gadolinium administration evaluate breakdown of the blood-brain barrier. Advanced physiological modalities include Dynamic Susceptibility Contrast (DSC) perfusion MRI to quantify relative cerebral blood volume (rCBV) and Proton Magnetic Resonance Spectroscopy (1H-MRS) to demonstrate elevated choline/creatine ratios, reduced N-acetylaspartate (NAA), and elevated 2-hydroxyglutarate spectral peaks.
- Histopathological Inspection: Formalin-fixed paraffin-embedded (FFPE) sections are stained with hematoxylin and eosin (H&E) to assess fundamental cellular features: nuclear pleomorphism, nuclear-to-cytoplasmic ratio, mitotic figure density, microvascular endothelial multilayering, and serpentine ischemic or pseudopalisading necrosis.
- Immunohistochemistry (IHC): An indispensable triaging tool. Astrocytic differentiation is confirmed via Glial Fibrillary Acidic Protein (GFAP) and S100 positivity. The R132H mutant-specific antibody evaluates IDH1 status; retained or lost nuclear expression of ATRX separates astrocytomas (loss) from oligodendrogliomas (retained); p53 staining reflects underlying gene mutation; and the Ki-67 (MIB-1) labeling index quantifies the active cellular proliferative fraction.
- Genomic and Molecular Profiling: Next-generation sequencing (NGS) panels identify non-canonical IDH1/2 mutations and evaluate BRAF, H3F3A, and HIST1H3B alterations. Droplet digital PCR (ddPCR) or comparative genomic hybridization (aCGH) detects CDKN2A/B homozygous deletion, while DNA methylation profiling using Illumina BeadArrays resolves diagnostically equivocal neoplasms against global reference epigenomic signatures.
10. Applications & Practical Significance
Accurate biological classification and grading of astrocytomas directly dictates clinical decision-making across neurosurgery, radiation oncology, and systemic medical oncology. Surgical management adheres to the modern oncological philosophy of “maximal safe resection.” Cytoreductive surgery serves a dual purpose: providing adequate tissue volume for complex histomolecular interrogation and relieving focal neurological mass effect. Extensive research demonstrates that achieving supratotal or gross total resection of both the contrast-enhancing and the non-enhancing T2/FLAIR hyperintense margins significantly correlates with prolonged overall survival and delayed malignant transformation, provided functional neurological integrity is preserved through intraoperative neuro-navigation, awake language testing, and subcortical motor evoked potential monitoring.
Following surgical stratification, adjuvant therapeutic pathways are heavily governed by WHO grade and molecular status. For patients harboring high-risk Grade 2 or Grade 3 IDH-mutant astrocytomas, adjuvant therapy standardly entails focal external beam fractionated radiation therapy (typically 54.0 to 59.4 Gy delivered in 1.8 Gy daily fractions) followed by systemic chemotherapy. Chemotherapeutic protocols include either alkylating monotherapy with temozolomide or the multi-agent PCV regimen (procarbazine, lomustine [CCNU], and vincristine).
In addition to oncological therapy, supportive neurological care is paramount. Corticosteroids (e.g., dexamethasone) are titrated to alleviate tumor-associated vasogenic edema and improve focal neurological deficits. Levetiracetam, lamotrigine, or lacosamide are deployed as first-line anticonvulsants to manage tumor-associated epilepsy, with careful selection to prevent drug-drug interactions with systemic oncolytics and hepatic enzyme induction.
11. Research & Empirical Evidence
Modern clinical management is grounded in extensive randomized clinical trials. The seminal RTOG 9802 trial demonstrated that in patients with high-risk low-grade gliomas (aged 40 years or older, or with subtotal resection), the addition of sequential PCV chemotherapy following radiotherapy nearly doubled median overall survival compared to radiation therapy alone (13.3 years versus 7.8 years), establishing the benchmark for aggressive combined adjuvant treatment.
Similarly, the long-term outcomes of the CATNON intergroup trial explored adjuvant strategies specifically in non-co-deleted, 1p/19q-intact anaplastic (Grade 3) astrocytomas. CATNON demonstrated that adjuvant temozolomide delivered after radiotherapy conferred significant overall survival benefits, particularly among patients whose tumors harbored somatic IDH1/2 mutations, proving that molecular subtyping is vital for predicting chemotherapeutic responsiveness.
The therapeutic horizon has been fundamentally altered by the development of brain-penetrant targeted small-molecule inhibitors. The landmark global Phase III INDIGO trial evaluated vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in patients with residual or recurrent Grade 2 IDH-mutant gliomas. Vorasidenib significantly prolonged progression-free survival compared to placebo (median 27.7 months versus 11.1 months) and dramatically delayed the required time to subsequent radiation and cytotoxic chemotherapy. This trial validated targeted metabolic inhibition as an efficacious therapeutic modality capable of fundamentally altering the natural course of early-stage diffuse astrocytomas.
12. Cultural & Cross-Cultural Considerations
Epidemiologically, diffuse astrocytomas exhibit curious demographic variations globally. High-income countries across North America, Northern Europe, and Australia report significantly higher age-standardized incidence rates of malignant gliomas (approximately 5 to 8 per 100,000 person-years) relative to nations in Sub-Saharan Africa, Latin America, and Southeast Asia (frequently reporting 2 to 4 per 100,000 person-years). While genuine environmental and genetic susceptibilities may play minor roles, cross-cultural disparities are largely attributed to health infrastructure inequalities, unequal access to magnetic resonance neuroimaging, shortages of specialized neuropathologists, and non-uniform population-based cancer registry reporting.
Furthermore, socioeconomic determinants of health dramatically impact clinical trajectory. In resource-rich settings, standard-of-care astrocytoma management involves routine next-generation sequencing, awake functional craniotomies, access to dedicated neuro-oncology tumor boards, and participation in clinical trials. Conversely, in low- and middle-income countries, patients frequently face delayed presentations with catastrophic neurological compromise, lack access to molecular assays necessary to satisfy current WHO diagnostic criteria, and experience critical shortages of radiotherapy facilities and adjuvant chemotherapy agents.
13. Criticisms, Debates & Limitations
Despite significant advancements, contemporary astrocytoma nosology and management face considerable scientific controversies and technical bottlenecks:
- The WHO 2021 “Molecular Inversion” Debate: In the updated classification, an IDH-wildtype astrocytoma exhibiting low-grade histology (lacking mitoses, microvascular proliferation, or necrosis) is upgraded to a CNS WHO Grade 4 Glioblastoma if it demonstrates EGFR amplification, TERT promoter mutation, or concurrent +7/-10 chromosome copy-number alterations. While biologically rigorous, some clinical trialists argue that patients with tiny, incidental, molecularly defined Grade 4 tumors may not share the identical hyper-aggressive natural history of patients presenting with massive, necrotic classic glioblastomas, complicating patient risk communication.
- Accessibility and Equity of Molecular Platforms: The reliance on expensive molecular technologies creates a two-tiered diagnostic landscape. Centers in developing nations without access to DNA methylation profiling, high-throughput sequencing, or fluorescence in situ hybridization are frequently unable to provide the definitive integrated diagnoses mandated by international consensus guidelines.
- Pseudoprogression vs. True Tumor Recurrence: Following chemoradiation with temozolomide, up to 30% of patients develop radiographic worsening characterized by enlarging contrast enhancement and expanding edema that mimics clinical recurrence. This phenomenon, known as pseudoprogression, represents an intense inflammatory, treatment-induced necrosis of the neurovascular bed rather than tumor proliferation. Accurately differentiating pseudoprogression from true recurrence remains a profound clinical challenge, often resulting in premature treatment termination or unnecessary repeat surgeries.
14. Related Terms & Distinctions
Accurate clinical diagnosis requires distinguishing astrocytoma from other intra-axial primary and secondary central nervous system lesions:
- Oligodendroglioma: A diffuse glioma that shares IDH mutations with diffuse astrocytoma, but is definitively characterized by the obligatory presence of whole-arm concurrent deletion of chromosomes 1p and 19q (1p/19q codeletion) and intact nuclear ATRX expression. Oligodendrogliomas generally exhibit a vastly superior prognosis, increased chemosensitivity to PCV, and classic “fried-egg” perinuclear halos under light microscopy.
- Glioblastoma (IDH-Wildtype): Formerly categorized under the umbrella of astrocytoma, glioblastoma is now reserved strictly for adult diffuse IDH-wildtype astrocytic tumors harboring microvascular proliferation, necrosis, or specific genomic markers (TERT, EGFR, +7/-10). It is radically more aggressive than an IDH-mutant Grade 4 astrocytoma, carrying an unadjusted historical median survival of 14 to 16 months despite maximal multimodal therapy.
- Ependymoma: A primary CNS neoplasm arising from the ependymal lining of the cerebral ventricular system or central canal of the spinal cord. Histopathologically defined by true perivascular pseudorosettes and ependymal rosettes, driven by distinct site-specific genomic alterations (e.g., ZFTA or YAP1 fusions supratentorially, PFA/PFB in the posterior fossa).
- Cerebral Metastasis: Secondary hematogenous dissemination from non-CNS primary solid malignancies (e.g., non-small cell lung cancer, breast carcinoma, melanoma). Metastases form sharply circumscribed nodular margins at gray-white matter junctions with dramatic vasogenic edema, contrasting sharply with the primary infiltrative parenchyma-permeating pattern of diffuse astrocytomas.
- Reactive Gliosis: A non-neoplastic, physiological hypertrophy and hyperplasia of native astrocytes occurring in response to parenchymal insults (infarction, multiple sclerosis demyelinating plaques, abscesses, trauma). Histologically, reactive astrocytes demonstrate rich, star-like processes, preserved spatial architecture without nuclear crowding, and complete absence of driver somatic mutations.
15. Summary / Key Takeaways
Astrocytomas constitute a diverse spectrum of primary neuroepithelial tumors unified by astrocytic morphology. The paradigm of neuro-oncology has transitioned permanently from purely descriptive micro-architectural grading toward an integrated histomolecular taxonomy, separating indolent circumscribed tumors (such as pilocytic astrocytoma) from infiltrative diffuse astrocytomas governed by IDH mutational status. In the modern era, comprehensive care requires maximal safe surgical resection guided by functional neuro-navigation, followed by risk-adapted adjuvant chemoradiotherapy and emerging molecular targeted therapies, such as dual IDH1/2 inhibitors, designed to control disease progression while preserving neurocognitive functional status.
Ultimately, treating patients with astrocytic tumors demands an agile, multidisciplinary approach that balances oncological aggression against the preservation of cognitive and neurological quality of life. As translational neuro-oncology continues to map out the intricate genomic, metabolic, and microenvironmental networks governing glioma biology, therapies will progressively transition from broad-spectrum cytoreductive interventions toward precision targeted strategies, delivering refined clinical outcomes for patients confronting this complex diagnosis.
References
- Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., & Ellison, D. W. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology, 23(8), 1231–1251. https://doi.org/10.1093/neuonc/noab106
- Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. The New England Journal of Medicine, 389(7), 589–601. https://doi.org/10.1056/NEJMoa2304194
- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330
- van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Rogers, L., Taal, W., Rudà, R., Weller, M., … Gorlia, T. (2021). Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study. The Lancet Oncology, 22(6), 813–823. https://doi.org/10.1016/S1470-2045(21)00090-5
- Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Delattre, J. Y., Hoang-Xuan, K., Cigolle, F., Fisher, B. J., Ashby, L. S., Bradshaw, P. C., Olson, J. J., Souhami, L., Jenkins, R. B., Curran, W. J., & Mehta, M. P. (2016). Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. The New England Journal of Medicine, 374(14), 1344–1355. https://doi.org/10.1056/NEJMoa1500925